NCT03595657CompletedPhase 2
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- CStone Pharmaceuticals
- Enrollment
- 80
- Locations
- 17
- Primary Endpoint
- Objective Response Rate (ORR) Assessed by IRRC
Study Overview
Brief Summary
This is a multicenter, single-arm, phase II study to evaluate the efficacy and safety of CS1001 monotherapy for Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma (ENKTL)
Detailed Description
Eligible subjects with rr-NKTL after prior asparaginase-based chemotherapy or chemo radiotherapy are planned to receive CS1001 1200 mg intravenous infusion every three weeks until progression of disease, intolerable toxicity, consent withdrawn, death. The primary endpoint of this trial is objective response rate (ORR), as assessed by independent radiological review committee (IRRC) based on Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject must have a histologically confirmed NKTL at study site.
- •Subject must have relapsed or refractory NKTL after prior asparaginase-based chemotherapy or chemo radiotherapy.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or
- •Subject must have at least one evaluable or measurable lesion per Lugano 2014 classification.
- •Subject must have adequate organ function and bone marrow function without severe hematopoietic disorder, or heart, lung, liver or kidney dysfunction or immune deficiency.
- •Subject must provide stained tumor tissue sections and corresponding pathological report or unstained tumor tissue sections (or tissue block) for central pathology review.
- •Subject with prior anti-cancer treatment can only be enrolled when the toxicity of prior anti-cancer treatment has recovered to baseline or ≤ Grade 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Exclusion Criteria
- •Invasive natural killer leukemia.
- •Concomitant with hemophagocytic syndrome.
- •Primary site in central nervous system (CNS) or CNS involvement.
- •Subjects currently participating in other clinical studies or use of any investigational drug within 4 weeks prior to the first dose of CS
- •Subjects who received systemic corticosteroid or any other immunosuppressive therapy within 14 days prior to the first dose of CS
- •Subjects who had prior chemotherapy, immune therapy, biological therapy as systemic treatment for cancer, within 28 days prior to the first dose of CS
- •Receipt of traditional medicinal herbal preparations with anti-tumor indications with 7 days prior to the first dose of CS
- •Known history of human immunodeficiency virus (HIV) infection and/or acquired immune deficiency syndrome.
- •Subjects with active hepatitis B or C infection.
- •Subjects with active tuberculosis infection.
- •Subjects who received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA-4 monoclonal antibody.
- •Female subjects who are pregnant or breast-feeding.
- •For more information regarding trial participation, please contact at cstonera@cstonepharma.com
Arms & Interventions
CS1001
Experimental
Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
Intervention: CS1001 (Biological)
Outcomes
Primary Outcomes
Objective Response Rate (ORR) Assessed by IRRC
Time Frame: From enrollment to end of follow-up, a median of 29 months
ORR assessed by the independent radiological review committee (IRRC) according to Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification
Secondary Outcomes
- Time to Response (TTR) Assessed by IRRC(From enrollment to end of follow-up, a median of 29 months)
- Complete Response Rate (CRR) Assessed by IRRC(From enrollment to end of follow-up, a median of 29 months)
- Duration of Response (DoR) Assessed by Investigators(From enrollment to end of follow-up, a median of 29 months)
- Objective Response Rate (ORR) Assessed by Investigators(From enrollment to end of follow-up, a median of 29 months)
- Partial Response Rate (PRR) Assessed by Investigators(From enrollment to end of follow-up, a median of 29 months)
- Partial Response Rate (PRR) Assessed by IRRC(From enrollment to end of follow-up, a median of 29 months)
- Complete Response Rate (CRR) by Investigators(From enrollment to end of follow-up, a median of 29 months)
- Time to Response (TTR) Assessed by Investigators(From enrollment to end of follow-up, a median of 29 months)
- Duration of Response (DoR) Assessed by IRRC(From enrollment to end of follow-up, a median of 29 months)
- Number of Participants With Adverse Events(From enrollment to end of follow-up, a median of 29 months)
Investigators
Study Sites (17)
Loading locations...
Similar Trials
Completed
Phase 2
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin LymphomaHodgkin LymphomaNCT03505996CStone Pharmaceuticals82
Completed
Phase 1
c-Met Second-Line Hepatocellular CarcinomaCarcinoma, HepatocellularNCT02115373Merck KGaA, Darmstadt, Germany66
Unknown
Phase 1
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Squamous Cell Carcinoma of Head and NeckNCT05027204CSPC ZhongQi Pharmaceutical Technology Co., Ltd.94
Active, not recruiting
Phase 2
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HUPolycythemia VeraNCT05485948PharmaEssentia49
Recruiting
Phase 1
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL PatientsEBV-Positive Diffuse Large B-Cell Lymphoma, NosNCT05577364Sun Yat-sen University54